CA SB 524 Comment Letter (2021)
PCMA delivers a comment letter to the chair of the Assembly committee on Business and Professions addressing steering and mail order proposed provisions.
OK Coalition Comment Letter to BoP (2023)
Coalition letter in opposition to a Board of Pharmacy proposed rule that would require temperature controlled packaging for all drug delivery, regardless of specific temperature
MA Bundle of Bills Testimony (2021)
PCMA submits testimny to the Joint Committee on Financial Services regarding a bucket list of bills addressing a wide range of PBM regulations.
CA SB 524 Comment Letter
PCMA delivers a comment letter to the sponsor of SB 602, a bill that aims to prohibit PBMs ability to steer patients to lower cost,
CA SB 524 Comment Letter
PCMA provides comment letter to the CA Senate Health Committee opposing SB 524, an anti-steering bill. If enacted, the bill would prohibit PBMs from offering
PCMA Comment Letter OR HB 485 (2019)
This letter was submitted by PCMA regarding OR HB485 dealing with mail order pharmacies and clarification on the pharmacy appeal process.
PCMA GA HB233 Veto Request Letter (2019)
This veto request letter was submitted by PCMA in regards to GA HB233, an anti-steering bill.
PCMA Comment Letter MA Joint Healthcare Finance Committee (2019)
This comment letter was submitted to the MA Joint Health Care Finance Committee regarding multiple PBM related pieces of legislation.
PCMA MT SB71 Veto Request Letter (2019)
This veto request letter was submitted by PCMA in regards to MT SB 71 which would require a single formulary and prevent mail order pharmacies
CO Drug Supply Chain Comment Letter (2019)
This comment letter submitted by PCMA outlines the PBM value proposition and highlights tools used by PBMs to restrain increasing prescription drug costs.
PCMA AR Comment Letter (2018)
This comment letter from PCMA that was sent to every Arkansas legislator provides a comprehensive overview of the value that PBMs provide to their clients,
PCMA Oppose Letter: H.R. 1316: The Prescription Drug Price Transparency Act
This document outlines PCMA’s opposition to H.R. 1316. would increase costs for government and Medicare Part D, TRICARE, and FEHBP enrollees alike, by tying the hands